 Drug Design
"Drug Design" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include pharmacokinetics, dosage analysis, or drug administration analysis.
| Descriptor ID |
D015195
|
| MeSH Number(s) |
E05.295.500 H01.158.703.007.675.500 H01.181.466.675.500
|
| Concept/Terms |
Drug Design- Drug Design
- Design, Drug
- Designs, Drug
- Drug Designs
Drug Modeling- Drug Modeling
- Drug Modelings
- Modeling, Drug
- Modelings, Drug
|
Below are MeSH descriptors whose meaning is more general than "Drug Design".
Below are MeSH descriptors whose meaning is more specific than "Drug Design".
This graph shows the total number of publications written about "Drug Design" by people in this website by year, and whether "Drug Design" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1992 | 0 | 1 | 1 | | 1995 | 1 | 0 | 1 | | 2001 | 0 | 1 | 1 | | 2002 | 1 | 0 | 1 | | 2004 | 1 | 0 | 1 | | 2006 | 0 | 1 | 1 | | 2007 | 0 | 3 | 3 | | 2008 | 1 | 2 | 3 | | 2009 | 1 | 1 | 2 | | 2011 | 1 | 2 | 3 | | 2012 | 3 | 0 | 3 | | 2013 | 2 | 2 | 4 | | 2014 | 1 | 2 | 3 | | 2015 | 1 | 0 | 1 | | 2017 | 0 | 1 | 1 | | 2018 | 0 | 1 | 1 | | 2019 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Design" by people in Profiles.
-
Cotter TG, Jensen DM. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy. Drug Des Devel Ther. 2019; 13:2565-2577.
-
Silva DA, Yu S, Ulge UY, Spangler JB, Jude KM, Labão-Almeida C, Ali LR, Quijano-Rubio A, Ruterbusch M, Leung I, Biary T, Crowley SJ, Marcos E, Walkey CD, Weitzner BD, Pardo-Avila F, Castellanos J, Carter L, Stewart L, Riddell SR, Pepper M, Bernardes GJL, Dougan M, Garcia KC, Baker D. De novo design of potent and selective mimics of IL-2 and IL-15. Nature. 2019 01; 565(7738):186-191.
-
Du H, Huang Y, Hou X, Quan X, Jiang J, Wei X, Liu Y, Li H, Wang P, Zhan M, Ai X, Lu L, Yuan S, Sun L. Two novel camptothecin derivatives inhibit colorectal cancer proliferation via induction of cell cycle arrest and apoptosis in vitro and in vivo. Eur J Pharm Sci. 2018 Oct 15; 123:546-559.
-
Schwartz JS, Tajudeen BA, Cohen NA. Medical management of chronic rhinosinusitis - a review of traditional and novel medical therapies. Expert Opin Investig Drugs. 2017 Oct; 26(10):1123-1130.
-
Meng D, Andre P, Bateman TJ, Berger R, Chen YH, Desai K, Dewnani S, Ellsworth K, Feng D, Geissler WM, Guo L, Hruza A, Jian T, Li H, Metzger J, Parker DL, Reichert P, Sherer EC, Smith CJ, Sonatore LM, Tschirret-Guth R, Wu J, Xu J, Zhang T, Campeau LC, Orr R, Poirier M, McCabe-Dunn J, Araki K, Nishimura T, Sakurada I, Hirabayashi T, Wood HB. Development of a novel tricyclic class of potent and selective FIXa inhibitors. Bioorg Med Chem Lett. 2015 Nov 15; 25(22):5437-43.
-
Florine EM, Miller RE, Liebesny PH, Mroszczyk KA, Lee RT, Patwari P, Grodzinsky AJ. Delivering heparin-binding insulin-like growth factor 1 with self-assembling peptide hydrogels. Tissue Eng Part A. 2015 Feb; 21(3-4):637-46.
-
Somberg J. OUS results, clinical studies and therapeutic innovation in America. Am J Ther. 2014 Jul-Aug; 21(4):233.
-
Macé C, Chugh SS. Nephrotic syndrome: components, connections, and angiopoietin-like 4-related therapeutics. J Am Soc Nephrol. 2014 Nov; 25(11):2393-8.
-
Mulshine JL, Avila R, Yankelevitz D, Baer TM, Estepar RS, Fenton L, Aldige CR. Application of high-resolution CT imaging data to lung cancer drug development: measuring progress: workshop IX. J Thorac Oncol. 2013 Nov; 8(11):1352-5.
-
Miller RE, Lu Y, Tortorella MD, Malfait AM. Genetically Engineered Mouse Models Reveal the Importance of Proteases as Osteoarthritis Drug Targets. Curr Rheumatol Rep. 2013 Aug; 15(8):350.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|